Eikmans M, van der Keur C, Anholts J, Drabbels J, van Beelen E, de Sousa Lopes S, et al. Primary Trophoblast Cultures: Characterization of HLA Profiles and Immune Cell Interactions. Front Immunol. 2022;13:814019 pubmed publisher

Heinkel F, Verstraete M, Cao S, Li J, Farber P, Stangle E, et al. Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics. MAbs. 2022;14:2141637 pubmed publisher

De Bacco F, Orzan F, Erriquez J, Casanova E, Barault L, Albano R, et al. ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. Cell Rep. 2021;36:109455 pubmed publisher

Sreevalsan S, Döring M, Paszkowski Rogacz M, Brux M, Blanck C, Meyer M, et al. MLLT6 maintains PD-L1 expression and mediates tumor immune resistance. EMBO Rep. 2020;:e50155 pubmed publisher

Ninio Many L, Hikri E, Burg Golani T, Stemmer S, Shalgi R, Ben Aharon I. miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines. Front Oncol. 2020;10:191 pubmed publisher

Joshi S, Rathore A. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study. BioDrugs. 2020;34:209-223 pubmed publisher

Robichaux J, Elamin Y, Vijayan R, Nilsson M, Hu L, He J, et al. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell. 2019;36:444-457.e7 pubmed publisher

Durst F, Grujovic A, Ganser I, Hoffmann M, Ugocsai P, Klein C, et al. Targeted transcript quantification in single disseminated cancer cells after whole transcriptome amplification. PLoS ONE. 2019;14:e0216442 pubmed publisher

Baccelli I, Gareau Y, Lehnertz B, Gingras S, Spinella J, Corneau S, et al. Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia. Cancer Cell. 2019;36:84-99.e8 pubmed publisher